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P rimary percutaneous coronary intervention (PCI) is the best therapeutic strategy for ST-segment–
elevation myocardial infarction (STEMI),  but patients 
who have experienced a STEMI remain at high risk of 
recurrent cardiovascular events such as congestive heart 
failure,  arrhythmia,  and sudden death [1 , 2].  One of 
the major predictors of mortality and morbidity in this 
patient population is the extent of myocardial necrosis 
[3].  Novel therapies that are able to reduce the infarct 
size are thus desired.
The efficacy of β-blockers for reducing infarct size is 
well established [4],  and current guidelines recom-
mend the early initiation of treatment with β-blockers 
in STEMI patients [2].  With respect to the benefit of 
intravenous β-blockers before reperfusion,  the 
METOCARD-CNIC (Effect of Metoprolol in Cardio-
protection During an Acute Myocardial Infarction) trial 
demonstrated that intravenous metoprolol before PCI 
reduced the infarct size as observed by cardiac magnetic 
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Early treatment with an oral β-blocker is recommended in patients with a ST-segment–elevation myocardial 
infarction (STEMI).  In this multicenter study,  we evaluated the effects of a continuous administration of landi-
olol,  an ultrashort-acting β-blocker,  before primary percutaneous coronary intervention (PCI) on myocardial 
salvage and its safety in STEMI patients.  A total of 47 Japanese patients with anterior or lateral STEMI under-
going a primary PCI within 12 h of symptom onset were randomized to receive intravenous landiolol (started at 
3 μg/min/kg dose and continued to a total of 50 mg; n = 23) or not (control; n = 24).  Patients with Killip class 
III or more were excluded.  The primary outcome was the myocardial salvage index on cardiac magnetic reso-
nance imaging (MRI) performed 5-7 days after the PCI.  Cardiac MRI was performed in 35 patients (74%).  The 
myocardial salvage index in the landiolol group was significantly greater than that in the control group 
(44.4 ± 14.6% vs. 31.7 ± 18.9%,  respectively; p= 0.04).  There were no significant differences in adverse events at 
24 h between the landiolol and control groups.  A continuous administration of landiolol before a primary PCI 
may increase the degree of myocardial salvage without additional hemodynamic adverse effects within the first 
24 h after STEMI.
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resonance imaging (MRI) [5].  However,  the EARLY-
BAMI (Early Beta-blocker Administration before reper-
fusion primary PCI in patients with ST-elevation 
Myocardial Infarction) trial showed no effect of intrave-
nous metoprolol before primary PCI on the infarct size 
[6].  The benefit of intravenous β-blockers before pri-
mary PCI in STEMI patients thus remains controver-
sial.  In addition,  because of the negative inotropic and 
chronotropic effects of β-blockers,  there are concerns 
over the risk of cardiogenic shock or heart failure with 
the use of β-blockers in the very-acute phase of a 
STEMI.
The intravenous β-blocker landiolol is ultrashort- 
acting,  with a very short half-life of approximately 
4 min.  Landiolol has a high β1/β2 selectivity ratio of 
approximately 255,  and a less negative inotropic effect 
compared to the β-blocker esmolol.  Landiolol provides 
a response at 0-2 min after administration [7 , 8].  
Kiyokuni et al.  reported that an early infusion of landi-
olol during primary PCI was associated with a higher 
grade of ST-segment resolution and a lower incidence of 
adverse events in the acute phase of STEMI compared 
to no treatment with landiolol [9].  However,  the bene-
fit of intravenous landiolol on infarct size before PCI in 
STEMI has not been established.  We conducted the 
present study to evaluate the effects of a continuous 
administration of landiolol before primary PCI on 
myocardial salvage revealed by MRI,  and its safety,  in 
patients with STEMI in an investigation with a prospec-
tive,  multicenter,  randomized design.
Patients and Methods
Study design. The effect of pre-landiolol treat-
ment on ischemic reperfusion injury in acute myocar-
dial infarction (PROTECTION) trial was a multicenter,  
prospective,  open-label,  randomized controlled trial.  
The primary focus of that trial was to determine 
whether STEMI patients receiving early intravenous 
landiolol before reperfusion would have a reduced 
infarct size compared with control subjects.  All patients 
received oral metoprolol within 24 h after reperfusion,  
as recommended by current clinical guidelines [2].  The 
present study was approved by the Okayama University 
Graduate School of Medicine,  Density and Pharma-
ceutical Sciences,  and the Okayama University Hospital 
Ethics Committee (m07012),  as well as the ethics com-
mittee of each hospital.  This trial was conducted in 
compliance with the Declaration of Helsinki.  This trial 
was registered in the UMIN Clinical Trials Registry 
(UMIN-CTR,  UMIN000012578).  All participants gave 
written informed consent to participate in the trial and 
to have their data published.
Patients. Patients eligible for enrollment were 
≥ 20 years old and were referred to undergo a primary 
PCI for a myocardial infarction with ST-segment eleva-
tion ≥ 0.2 mV in two or more contiguous precordial 
leads (one of which should be V2,  V3,  V4,  V5 or V6).  
A STEMI was diagnosed when the patient was admitted 
with chest pain that lasted for 30 min,  with an 
ST-segment elevation of ≥ 0.2 mV in at least 2 contigu-
ous leads,  and an elevation of creatine kinase (CK) or its 
MB isozyme to at least twice the normal levels.  The 
exclusion criteria were Killip class III to IV,  an esti-
mated time of symptom onset to reperfusion of > 24 h,  
systolic blood pressure persistently < 120 mmHg,  PR 
interval > 240 ms,  heart rate < 60/min,  left ventricular 
(LV) ejection fraction < 30%,  history of coronary artery 
bypass surgery,  prior myocardial infarction or hemodi-
alysis,  active treatment with any β-blocker,  and the 
implantation of a pacemaker or a cardioverter defibril-
lator.  All of the patients were Japanese.
Interventions and study procedures. Patients 
fulfilling all criteria who provided written informed 
consent to participate in this study were enrolled and 
subsequently randomized (1 : 1) to receive continuous 
intravenous landiolol or not (control).  In the landiolol 
group,  an intravenous infusion of landiolol (Ono 
Pharmaceutical Co.,  Osaka,  Japan; 3 μg/kg/min) was 
started just after randomization before PCI [9].  This 
dose was continued during and after the PCI procedure 
until a total dose of 50 mg was reached.  An unsched-
uled discontinuation of landiolol was left to the physi-
cian’s discretion.  Randomization was performed using 
a computer-generated random sequence web response 
system.  Patients were stratified by age (< 60 years,  ≥ 60 
years),  sex,  and infarct-related artery (left anterior 
descending coronary artery vs. other artery).  A cardiac 
MRI examination was scheduled 5-7 days after infarc-
tion for each patient.
Outcomes. The primary outcome of this study 
was the myocardial salvage index on MRI.  The pre-
specified major secondary outcomes were the infarct 
size quantified by MRI and the infarct size estimated by 
the peak CK and CK-MB values.  The major safety sec-
ondary outcome was the incidence of major adverse 
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cardiac events,  defined as a composite of death,  malig-
nant ventricular arrhythmia,  cardiogenic shock,  and 
atrioventricular block within 24 h after PCI.
PCI procedure. Before undergoing a PCI,  all 
patients received 200 mg aspirin and 300 mg clopido-
grel.  Each PCI was performed with conventional tech-
niques by the femoral or radial approach.  Intravenous 
heparin (10,000 IU) was administered after arterial 
access was obtained,  to achieve an activated clotting 
time > 200 sec.  Intravenous heparin was continued for 
48 h after an angioplasty followed by stent deployment.  
The postprocedural antithrombotic therapy consisted of 
100 mg aspirin daily and 75 mg clopidogrel daily.  No 
patients received glycoprotein inhibitors during the 
study period.
After their PCI,  the patients received optimal medi-
cal therapy such as dual antiplatelet agents and statins,  
based on published guidelines [10].  A successful PCI 
was defined based on the definition of angiographic and 
procedural success in the guidelines for PCI [11].  Once 
the planned intravenous landiolol infusion was com-
pleted,  all patients received oral metoprolol within 24 h,  
as recommended by current clinical guidelines [2].
MRI acquisition. The myocardial salvage index 
value and the infarct size were determined with the use 
of cardiovascular MRI at 5-7 days after the patients’ 
acute myocardial infarction.  The MRI studies were per-
formed using a 3.0 T scanner (MAGNETOM Verio,  
Siemens,  Erlangen,  Germany).  Short-axis slices cover-
ing the whole ventricle using a T2-weighted turbo 
inversion recovery magnitude sequence (repetition time,  
2 × R-R interval [2 heartbeats]; echo time,  67 msec;  
inversion time,  150 msec,  flip angle 180°; voxel size 
1.4 × 1.4 × 8.0 mm) were obtained using a body coil.  
Late enhancement images covering the whole ventricle 
were acquired approximately 10 min after an intrave-
nous administration of 0.2 mmol/kg body weight of 
gadoterate meglumine (Magnescope; Guerbert Japan,  
Tokyo; Fuji Pharma,  Tokyo).  A phase-sensitive inver-
sion recovery sequence (repetition time,  2 × R-R inter-
val [2 heartbeats]; echo time,  1.48 msec; flip angle,  
40°; voxel size,  1.9 × 1.4 × 8.0 mm) was used for image 
acquisition.
MRI analysis. All MRI analyses were performed 
independently by the core laboratory at Okayama 
University.  Data were quantified with dedicated soft-
ware (QMass MR 7.5; Medis,  Leiden,  Netherlands) 
(Fig. 1).  The following information was obtained in all 
MRI studies: the LV mass,  the myocardium at risk,  
and the infarcted myocardium.  The infarcted myocar-
dium (grams of LV tissue) was defined by the extent of 
abnormal delayed enhancement,  and the myocardium 
at risk (grams of LV tissue) was defined by the extent of 
edema (high signal intensity on T2-weighted short T1 
inversion-recovery images) [12].  The myocardial sal-
vage index was defined as the difference between the 
value of the myocardium at risk and that of the 
infarcted myocardium normalized to the myocardium 
at risk.
Statistical analyses. Based on previous studies,  
we estimated that the relative reduction in the myocar-
dial salvage index in the landiolol group would be 13% 
lower than that in the control group [5 , 13].  The stan-
dard deviation of the myocardial salvage index was 
estimated as 0.22.  A minimum of 92 patients (46 patients 
per group) was required to provide 80% power with a 
two-sided α-level of 0.05 by Student’s t-test between the 
2 groups.
Continuous variables are expressed as the mean ± 
standard deviation or the median (interquartile range).  
Dichotomous variables are expressed as the number 
(proportion).  Differences in continuous variables 
between the 2 groups were analyzed by the paired 
Student’s t-test or Mann-Whitney U-test,  as appropriate.  
Categorical data were compared by Fisher’s test.  The 
MRI data,  peak CK,  and peak CK-MB values were ana-
lyzed by an analysis of covariance (ANCOVA) without 
and with adjustment for the three stratification variables 
(age,  sex,  and infarct-related artery) and current or 
former smoking.  Differences in the interobserver 
reproducibility were compared using a Bland-Altman 
plot.  The limits of agreement were defined as the mean 
difference ± twofold standard deviation (SD) of the dif-
ference,  and are expressed as the mean difference (± 
limit of agreement).  All reported p-values were two-
sided,  and p-values < 0.05 were considered significant.  
The statistical analyses were performed using statistical 
software (SPSS software ver. 24; IBM Co.,  Armonk,  
NY,  USA).
Results
Study population. Between July 2013 and April 
2016,  47 patients were randomized to receive an intra-
venous landiolol infusion (n = 23) or intravenous saline 
infusion (n = 24,  control subjects) (Fig. 2).  After ran-
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Fig. 1　 Magnetic resonance imaging (MRI) analysis of the area at risk and infarcted myocardium.  MRI short-axis images obtained at the 
same left ventricular level in a patient in the PROTECTION trial.  The MRI was performed at 7 days post-ST segment elevation myocardial 
infarction (STEMI).  A,  The area of delayed enhancement (infarcted area,  red area in the anterior interventricular septum); B,  The area at 
risk at the same level of the left ventricle (blue area in the interventricular septum); C,  Corresponds to panel A after the automatic quanti-
fication of the area at risk.  Quantification of the infarct was also performed.  The area of necrosis was smaller than the area at risk.
Patients eligible (n=47)
Landiolol infusion from pre-PCI (n=23) Control (saline infusion, n=24)
Takotsubo cardiomyopathy (n=1)
Vasospastic angina (n=1)





Prior myocardial infarction (n=1)
MRI performed and 
analyzed primary outcome (n=17)
MRI performed and 




Hypotension during PCI (n=1)Hypotension during PCI (n=1)
Fig. 2　 The CONSORT flow diagram of this study.  MRI, -; ,  magnetic resonance imaging; PCI,  percutaneous coronary intervention.
domization,  7 patients (14%) were not scheduled for 
MRI,  based on our study’s exclusion criteria.  Of the 
patients scheduled for MRI,  3 (6%) patients did not 
undergo MRI because of renal insufficiency (n = 1) or 
technical problems with the magnet (n = 2).  Thus,  35 
patients (17 receiving intravenous landiolol and 18 con-
trols) had MRI data available for the primary outcome.  
Of the patients who underwent MRI,  there were no 
significant differences in any of the baseline character-
istics (Table 1).
Outcomes. The interobserver reproducibly of the 
myocardial salvage index on MRI was assessed by a cor-
relation analysis and Bland-Altman plot.  The correla-
tion coefficient between observers was 0.88 (p < 0.01).  
The interobserver variability was low,  with a mean bias 
of 1.3% (95% limits of agreement,  −3.8% to 6.3%).  The 
MRI data are presented in Table 2 and Fig. 3.
There were no significant differences in the unad-
justed or adjusted absolute weights of the LV mass,  
myocardium at risk,  and infarcted myocardium 
between the landiolol and control groups (Table 2,  
Fig. 3A , B).  There were also no significant differences in 
the unadjusted or adjusted proportions of infarcted 
myocardium in LV between the groups (Table 2).  
However,  the unadjusted and adjusted myocardial sal-
vage index values in the landiolol group were signifi-
cantly greater than those in the control group (Table 2,  
Fig. 3C).  The adjusted mean peak CK values in the 
landiolol and control groups were 3,102 IU/L and 
3,140 IU/L,  respectively (adjusted difference,  −37 IU/L;  
95% confidence interval [95%CI],  −1,651 to 1,576IU/L;  
p = 0.96).  The adjusted mean peak CK-MB values were 
324 IU/L and 363 IU/L in the landiolol and control 
groups,  respectively (adjusted difference,  −39 IU/L;  
95%CI,  −228 to 150 IU/L; p = 0.68) (Fig. 3D).
The median length of time from the patient’s arrival 
at the emergency room to the start of landiolol infusion 
did not differ significantly between the landiolol and 
control groups (31 min [26-62 min] and 35 min [26-
68 min],  respectively; p = 0.85).  The total infusion time 
of landiolol also did not differ significantly between the 
landiolol and control groups (254 ± 42 min and 
275 ± 58 min,  p = 0.23).  There was no significant asso-
ciation of the myocardial salvage index with the length 
of time from the arrival at the emergency room to the 
start of landiolol infusion or with the total infusion time 
of landiolol (p = 0.55 and p = 0.81,  respectively).
Safety data. The systolic blood pressure at the 
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Table 1　 Baseline characteristics of the patients










Age,  years 64±11 67±13 61±11.8 68±11.5 0.07
Male 21 (91) 21 (87) 16 (94) 16 (89) 0.58
Body mass index,  kg/m2 23.6±2.8 23.9±3.4 24.1±2.9 23.3±3.3 0.48
Hypertension 15 (65) 15 (62) 10 (59) 11 (61) 0.89
Dyslipidemia 9 (3) 8 (33) 5 (29) 6 (33) 0.80
Diabetes mellitus 7 (30) 6 (25) 7 (41) 4 (22) 0.22
Current smoker 16 (69) 9 (37) 15 (88) 11 (61) 0.06
Ischemia duration,  min＊＊ 219±101 273±140 233±104 242±108 0.81
Killip class I at recruitment 23 (100) 24 (100) 17 (100) 18 (100) 1.00
Infarct artery lesion,  LAD/LCX 21/0 21/1 17/0 17/1 0.32
TIMI grade 0-1 flow before PCI 21 (91.3) 22 (91.7) 17 (100) 18 (100) 1.00
Successful PCI 21 (100) 22 (100) 17 (100) 18 (100) 1.00
SBP at the recruitment,  mmHg 142±18 144±19 142±18 145±18 0.63
HR at the recruitment,  bpm 85±14 81±13 84±11 77±12 0.07
SBP at the starting PC,  mmHg 162±21 165±32 162±21 167±26 0.54
HR at the starting PCI,  bpm 83±14 85±14 85±13 85±14 0.92
＊Comparison between patients undergoing magnetic resonance imaging (MRI).  ＊＊Mean ischemia duration from symptom onset to reper-
fusion.  DBP,  diastolic blood pressure; HR,  heart rate; LAD,  left anterior descending coronary artery; LCX,  left circumflex coronary 
artery; PCI,  percutaneous coronary intervention; SBP,  systolic blood pressure; TIMI,  thrombolysis in myocardial infarction.
start of the PCI was significantly higher than that at 
recruitment in both the landiolol group and the control 
group (p < 0.01,  for both).  However,  there were no sig-
nificant differences between heart rate at the start of the 
PCI and heart rate at recruitment in either the landiolol 
group or control group (p = 0.87,  p = 0.14,  respectively) 
(Table 1).  The prespecified safety endpoint was the 
incidence of major adverse cardiac events within 24 h 
after PCI in all patients (the entire study population).  
There were 2 events (8.7%) in the landiolol group (one 
hypotension,  one non-sustained ventricular tachycar-
dia associated with reperfusion) and 2 events (8.3%) in 
the control group (one hypotension,  one non-sustained 
ventricular tachycardia associated with reperfusion).  
The uses of a continuous landiolol infusion from 
pre-reperfusion did not increase the incidence of major 
adverse cardiac events.
Discussion
The key finding of the present study was that the 
continuous administration of landiolol before the pri-
mary PCI in patients with an anterior or lateral STEMI 
increased the degree of myocardial salvage on MRI 
within the first 24 h after STEMI,  with no additional 
hemodynamic adverse effects.  Despite the findings 
from several investigations [5 , 9 , 14 , 15],  the effects of 
intravenous metoprolol or a continuous administration 
of landiolol or esmolol on the infarct size before PCI in 
STEMI patients remain unclear.
In the present study,  there was a significant differ-
ence in the primary outcome,  i.e.,  the myocardial sal-
vage index,  but not in the infarct myocardium,  on 
MRI.  This discrepancy may be explained by the greater 
myocardium at risk and smaller infarcted myocardium 
in the landiolol group compared to the control group,  
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Fig. 3　 The effect of the intravenous landiolol administration on infarct size was evaluated by MRI at 5-7 days after infarction.  A,  
Myocardium at risk; B,  Infarct size; C,  Salvage index.  Bars: mean±95%CI.
Table 2　 Magnetic resonance imaging data






Mean (SD) Mean (SD) Difference (95% CI) P value Difference (95% CI) P value
LV mass,  g 119.6±21.7 116.2±22.9 3.45 (-11.9 to 18.9) 0.65 2.9 (-13.6 to 19.6) 0.72
Myocardium at risk,  g 49.6±16.9 39.5±20.4 10.1 (-2.8 to 23.1) 0.12 9.0 (-5.1 to 23.1) 0.20
Infarcted myocardium,  g 24.7±10.3 26.8±19.4 -2.1(-112.9 to 8.7) 0.69 -3.8 (-15.9 to 8.3) 0.50
Infarcted myocardium,  % LV 20.8±8.87 22.4±12.7 -1.7 (-9.3 to 5.9) 0.66 -2.4 (-10.9 to -6.3) 0.58
Myocardial salvage index,  % 44.4±14.6 31.7±18.9 12.7 (0.9 to 24.4) 0.04 13.8 (0.6 to 27.2) 0.04
＊Adjusted by age,  sex,  infarct-related artery,  and current smokers.
Myocardial salvage index was defined as the difference between the weight of myocardium at risk and the weight of infarcted myocardium 
normalized to the weight of myocardium at risk.  CI,  confidence interval; SD,  standard deviation; LV,  left ventricular.
because the myocardial salvage index is calculated as 
(myocardium at risk − infarct myocardium) / myocar-
dium at risk.  Our study included patients with anterior 
or lateral STEMI,  and the adjustment of the myocar-
dium at risk between the 2 groups was difficult before 
the PCI due to the limited time and limited number of 
measures for the estimation of infarct size.  In the 
METOCARD-CNIC and EARLY-BAMI trials [5 , 14],  
the myocardium at risk was similar between the metop-
rolol and control groups.  The number of patients 
undergoing MRI in the present study was small.  Thus,  
despite our finding of a significant difference in the 
myocardial salvage index,  the interpretation of the 
increased myocardial salvage index should be consid-
ered with caution.
We found no additional hemodynamic adverse 
effects within the first 24 h after STEMI at the dose of 
3 μg/kg/min of landiolol.  We adopted this dose based 
on a previous study of STEMI patients [16],  which con-
trasts with the 1 μg/kg/min of landiolol used in another 
study of patients with LV dysfunction and atrial fibrilla-
tion [17].  In the present study,  the systolic blood pres-
sure and heart rate did not decrease after the continuous 
administration of landiolol,  and there were no signifi-
cant differences in the incidence of hypotension during 
PCI between the landiolol and control groups.  
Although one patient in each group had to stop taking 
landiolol during the primary PCI because of hypoten-
sion,  the vital signs of those patients recovered within a 
few minutes after the discontinuation of the agent.  
Because our study included patients in Killip class I,  the 
benefits of β-blockers before reperfusion in patents with 
hemodynamic instability remain unknown.  Although 
the short half-life of landiolol may have some advantage 
in avoiding adverse events,  further studies are required 
to confirm the optimal dose of landiolol for STEMI 
patients.
This study evaluated the effect of landiolol on the 
myocardial salvage index,  but not on the LV ejection 
fraction.  The current guidelines recommend risk strat-
ification in all patients hospitalized for STEMI.  As a 
part of the risk assessment,  the resting LV ejection frac-
tion should always be measured before discharge,  
because it is one of the strongest prognostic predictors.  
Data regarding the patients’ LV function on MRI were 
not available in our study.  However,  Hanada et al.  
demonstrated that a continuous administration of 
landiolol just after PCI in STEMI patients improved the 
LV ejection fraction assessed at 6 months of recovery 
[16].  The quantification of salvaged myocardium on 
MRI has also been proposed as a measure of risk assess-
ment after STEMI.  A recent meta-analysis demon-
strated that the myocardial salvage index measured by 
T2-weighted and T1-weighted late gadolinium 
enhancement MRI provides prognostic information 
about the risk of major cardiac events [18].  Thus,  the 
myocardial salvage index may be a useful measure after 
STEMI.
Although some beneficial mechanisms of early 
intravenous β-blockers have been reported,  the exact 
mechanisms of action remain unclear.  A STEMI results 
in a substantial and sustained release of catecholamines.  
β-blockers reduce the heart rate and cardiac contractil-
ity and thus decrease the myocardial oxygen consump-
tion of the ischemic myocardium [19].  Landiolol can 
also exert direct anti-inflammatory actions,  antioxidant 
effects,  and stabilization of the calcium handling of car-
diomyocytes [20–23].  These effects may attenuate isch-
emia–reperfusion injury.
The present study has some limitations.  It was a 
prospective,  randomized,  open,  blinded end-point 
(PROBE) trial,  although the evaluators of all outcomes 
were blinded to the patients’ treatment allocation.  We 
cannot completely rule out the influence of this design 
on the results.  Second,  the predefined sample size of 92 
was not achieved.  The study was designed to continue 
for almost 2 years,  with an enrollment period from July 
2013.  However,  our study population did not reach the 
number required for sufficient statistical power during 
the prespecified enrollment period.  We therefore 
extended the enrollment period to 3 years until April 
2016.  Unfortunately,  the study included only 35 
patients undergoing MRI,  and we were unable to con-
tinue the enrollment of new patients because of a short-
age of funds.  Thus,  the number of patients analyzed in 
this study was small.  Further research is needed to 
obtain robust evidence of the effect of landiolol on 
myocardial salvage after STEMI.  In addition,  the study 
population was comprised of only Japanese patients.  
The results may not be applicable to other ethnic groups.
In conclusion,  in patients who have experienced an 
anterior or lateral STEMI,  a continuous administration 
of landiolol before primary PCI may increase the degree 
of myocardial salvage without additional significant 
hemodynamic adverse effects.  Further evidence is 
needed to determine the precise effects of landiolol on 
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the reduction of infarct size and longer-term prognosis 
in a larger clinical trial.
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